Topic

Uptravi (selexipag)

A collection of 29 issues

If Uptravi (Selexipag) Isn't Approved by UnitedHealthcare in North Carolina: Formulary Alternatives & Exception Paths

Answer Box: When UnitedHealthcare Denies Uptravi (Selexipag) in North Carolina UnitedHealthcare requires step therapy before approving Uptravi (selexipag) for pulmonary arterial hypertension. You'll need to try formulary alternatives first—typically PDE5 inhibitors (sildenafil, tadalafil) or endothelin receptor antagonists (ambrisentan, bosentan)—unless you qualify for an exception. If denied
6 min read

How to Get Uptravi (Selexipag) Covered by UnitedHealthcare in Texas: Complete Guide to Prior Authorization, Appeals, and Approval

Answer Box: Getting Started To get Uptravi (selexipag) covered by UnitedHealthcare in Texas: Your doctor submits a prior authorization through the UnitedHealthcare Provider Portal or by calling 888-397-8129. You'll need documented WHO Group I PAH diagnosis, functional class II-IV status, and evidence of step therapy compliance or contraindications
6 min read

How to Get Uptravi (Selexipag) Covered by UnitedHealthcare in Ohio: Complete Guide with Forms, Appeals & Contact Info

Answer Box: Getting Uptravi Covered by UnitedHealthcare in Ohio UnitedHealthcare requires prior authorization for Uptravi (selexipag) in Ohio through OptumRx. The fastest path to approval: (1) Submit PA request via the UnitedHealthcare Provider Portal with complete PAH documentation, (2) Include WHO Group I PAH diagnosis, functional class, and prior therapy
5 min read

How to Get Uptravi (Selexipag) Covered by UnitedHealthcare in Virginia: Prior Authorization, Appeals & Approval Scripts

Answer Box: Quick Path to Uptravi Coverage To get Uptravi (selexipag) covered by UnitedHealthcare in Virginia: Your pulmonologist must submit prior authorization with confirmed WHO Group I PAH diagnosis, right heart catheterization results, and documentation of symptomatic disease (functional class II-IV). Most approvals require evidence of prior PAH therapy trials.
6 min read